Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
Mené sur 235 patients atteints d'une leucémie promyélocytaire aiguë, cet essai de phase III compare l'efficacité, du point de vue de la qualité de vie, et la toxicité du trioxyde d'arsenic et de l'idarubicine, en combinaison avec l'acide tout-trans rétinoïque
The treatment of patients with acute promyelocytic leukaemia has changed dramatically in the past two decades, with the disease now regarded as one of the most curable haematological neoplasms. The recognition of the high sensitivity of acute promyelocytic leukaemia cells to anthracyclines and the introduction of all-trans retinoic acid (ATRA) therapy have led to the de-intensification of therapy, with more recent studies showing that the omission of cytarabine is feasible, at least in standard-risk patients.
The Lancet Oncology , commentaire, 2014